Clinical Trials
11
Trial Phases
4 Phases
Drug Approvals
4
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Blue Earth Diagnostics
- Target Recruit Count
- 52
- Registration Number
- NCT06604442
- Locations
- 🇺🇸
Mayo Clinic, Jacksonville, Florida, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
🇺🇸Tower Urology, Los Angeles, California, United States
Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE)
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Blue Earth Diagnostics
- Target Recruit Count
- 23
- Registration Number
- NCT04410367
- Locations
- 🇺🇸
John Wayne Cancer Institute at Providence St. John's Health Center, Santa Monica, California, United States
🇺🇸Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸Miami Cancer Institute, Miami, Florida, United States
Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Blue Earth Diagnostics
- Target Recruit Count
- 151
- Registration Number
- NCT04410133
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence
- Conditions
- Prostate Cancer
- Interventions
- Drug: rhPSMA-7.3 (18F) InjectionDiagnostic Test: Positron emission tomography scan
- First Posted Date
- 2019-12-05
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Blue Earth Diagnostics
- Target Recruit Count
- 391
- Registration Number
- NCT04186845
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Tower Urology, Los Angeles, California, United States
🇺🇸University of California Irvine Medical Center (UCIMC), Orange, California, United States
Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.
- Conditions
- Prostate Cancer
- Interventions
- Drug: rhPSMA-7.3 (18F) InjectionDiagnostic Test: Positron Emission Tomography scan
- First Posted Date
- 2019-12-05
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Blue Earth Diagnostics
- Target Recruit Count
- 356
- Registration Number
- NCT04186819
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Tower Urology, Los Angeles, California, United States
🇺🇸University of California Irvine Medical Center (UCIMC), Orange, California, United States
- Prev
- 1
- 2
- Next
News
FDA Approves Posluma, First Radiohybrid PSMA-Targeted PET Imaging Agent for Prostate Cancer
The FDA has approved flotufolastat F 18 injection (Posluma) for PET imaging of PSMA-positive lesions in prostate cancer patients, aiding in metastasis detection and recurrence assessment.